Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Antibody Discovery Services
Overview
Target Analysis & Immunization
Antibody Discovery & Characterization
Developability Profiling
Optimization & Engineering
Preclinical Services
Protein Production
Overview
 
Online Store

Explore now

See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
AI Technology
LENSai Applications
The LENSai Difference
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Resources
Antibody Discovery Resources
AI Technology Resources
IPA Collective
Resource Spotlight
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Company
Overview
Leadership
Investor Relations
Careers
Locations
Contact Us
News
News & Press Releases
Events
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

In the News

Contact Us

IPA News
June 13th, 2023
IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
VICTORIA, British Columbia, June 13, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration...
June 6th, 2023
IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
VICTORIA, British Columbia, June 6, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and...
May 30th, 2023
IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
VICTORIA, British Columbia May 30, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has...
April 24th, 2023
LENSᵃⁱ Update: IPA’s BioStrand LENSᵃⁱ™ integrates advanced HYFT™ technology to enhance LLMs and accelerate antibody discovery.
Dr. Dirk Van Hyfte, Head of Innovation and Co-Founder at BioStrand, stated, “The integration of HYFT technology into our LLMs marks a transformative moment in biotechnology." See full announcement
December 8th, 2022
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFT™ and Accelerates in Silico Drug Discovery Developments
Structural HYFT Technology is used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary Scale Modeling (ESM)-2 Fold HYFT Technology explores formal and explicit biologically relevant knowledge and...
November 29th, 2022
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
VICTORIA, VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA, PA, November 30, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV...
November 22nd, 2022
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
VICTORIA, BRITISH COLUMBIA (CANADA), November 22, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares...
September 14th, 2022
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
VICTORIA, BRITISH COLUMBIA (CANADA), September 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has shared positive results of a...
September 14th, 2022
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
Structural HYFTs fully indexed and integrated in structure-function workflow LENSai® data management platform successfully launches hyper-scalable solution for partner access, integrating multiple data layers at once Company shares BioStrand...
August 29th, 2022
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm Polytope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
VICTORIA, BRITISH COLUMBIA (CANADA), August 29, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope®...
July 28th, 2022
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021 The Company achieved record revenues of $5.2 million for the three months ended April 30, 2022, an increase of 7.4% over the same period last...
July 28th, 2022
Capabilities deck
IPA_CapabilitiesDeck_2022
July 26th, 2022
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA), July 26, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and...
March 29th, 2022
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
New Platform Integrates Sequence Data and Information from Entire Biosphere • Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. • Platform is based on a proprietary biological discovery called HYFT™ patterns,...
March 8th, 2022
ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET
VICTORIA, BRITISH COLUMBIA March 8, 2022 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a...
January 18th, 2022
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
IPA Europe’s Oss laboratories make a move to new Centre of Excellence facilities in Oss, Netherlands, with progressive environmental impact measures. VICTORIA, BRITISH COLUMBIA and OSS, The Netherlands, January 17, 2022 / – IMMUNOPRECISE ANTIBODIES...
January 3rd, 2022
ImmunoPrecise Antibodies Announces Grant of Stock Options
VICTORIA, British Columbia – January 3, 2022–IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board of directors has approved the...
December 19th, 2021
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
VICTORIA, BRITISH COLUMBIA December 20, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSX VENTURE: IPA) and ChemPartner Biologics Co. Ltd. (“ChemPartner”) today announced their global antibody manufacturing...
December 13th, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
VICTORIA, BRITISH COLUMBIA December 13, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for...
December 7th, 2021
Antibody Engineering & Therapeutics – San Diego
ImmunoPrecise (IPA) will be attending the Antibody Engineering & Therapeutics conference being hosted December 12-16, 2021. Delivered as a Hybrid Event, available in-person at the Marriott Marquis San Diego as well as online. IPA will be hosting an...
December 7th, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
The Company to host an earnings conference call via webcast on December 13, 2021 at the close of market VICTORIA, BRITISH COLUMBIA December 7th, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a...
November 29th, 2021
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
Polytope™ Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis VICTORIA, BRITISH COLUMBIA (CANADA), November 30, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is providing an...
November 24th, 2021
The BioTech Pharma Summit
ImmunoPrecise (IPA) will be attending The BioTech Pharma Summit November 29-30, 2021 being held in Porto, Portugal and virtually. BioTech Pharma Summit brings together a large number of pharma industry buyers and sellers all under one roof. To learn...
November 10th, 2021
IPA Announces Resignation of Director
VICTORIA, BRITISH COLUMBIA November 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective...
October 12th, 2021
13th Annual PEGS Europe
ImmunoPrecise will be exhibiting at the 13th annual PEGS Europe. PEGS (Protein & Antibody Engineering Summit) is one of the most significant European events for all aspects of proteins and antibody engineering, offering keynote speakers, seminars,...
October 12th, 2021
BIO-Europe
The international BIO-Europe® 2021 will be held digitally from October 25-28, 2021. BIO-Europe brings the global biopharma and investment leaders together to build partnerships and facilitate innovation and medical breakthroughs. ImmunoPrecise...
September 9th, 2021
19th Annual Discovery on Target
ImmunoPrecise Antibodies (IPA) will be participating in the 19th Annual Discovery on Target (DOT), being held in Boston, MA, and virtually, September 27-30. The event will host a variety of keynote speakers, short courses, roundtables, and...
September 9th, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
VICTORIA, BRITISH COLUMBIA September 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for...
September 8th, 2021
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
VICTORIA, BRITISH COLUMBIA September 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss,...
September 3rd, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market VICTORIA, BRITISH COLUMBIA September 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a...
July 28th, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
• Total revenue of $17.9 million, up 27% from $14.1 million in fiscal 2020• Successfully dual listed to Nasdaq Global Market, subsequently raised USD$25 million in bought deal offering• Advanced proof-of-concept for TATX-03 COVID-19 program lead...
July 15th, 2021
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
The Company to host an earnings conference call via webcast on July 28, 2021, after the close of market VICTORIA, BRITISH COLUMBIA July 15, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in...
June 17th, 2021
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
Treatment with TATX-03a substantially reduced bronchitis and tracheitis severity in preclinical studies -New histopathology data show that the significantly reduced viral load observed after prophylactic and therapeutic treatment with TATX-03a is...
June 16th, 2021
6th Annual CAR-TCR Summit
The 6th Annual CAR-TCR Summit returns in 2021 as the industry-leading comprehensive forum with one goal: to engineer a disease-free world. At the event, over 150 speakers will lead discussions on many topics from commercial pipeline development to...
June 10th, 2021
HubXchange West Coast 2021
We will be attending US West Coast HubXchange from September 20th-22nd 2021. HubXchange specializes in delivering high-level content, intelligence and connections to the global Life Sciences community by hosting outstanding business Xchanges. These...
June 6th, 2021
ImmunoPrecise to Present at Antibody Engineering & Therapeutics Europe
At this year’s Antibody Engineering & Therapeutics Europe, Dr. Debby Kruijsen will be present the scientific briefing Identification of Unique Antibodies by Parallel Sourcing Chicken and Human B-cell Repertoires Using Innovative Technologies. Our...
June 2nd, 2021
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche
VICTORIA, BRITISH COLUMBIA June 2, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that Dr. Yasmina Abdiche,...
April 28th, 2021
ImmunoPrecise To Attend Alliance For Cancer Gene Therapy Summit 2021
We are pleased to be attending the Alliance For Cancer and Gene Therapy Summit 2021. The summit is being held virtually April 29th 2021, containing multiple panels led by industry leaders to discuss the latest innovations in cancer drugs and...
April 21st, 2021
ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record
VICTORIA, BRITISH COLOMBIA April 21, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and...
April 8th, 2021
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
Potential to Treat Parkinson’s and Other Neurodegenerative Diseases VICTORIA, BRITISH COLUMBIA April 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic...
March 17th, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year
• Immunoprecise and Genmab enter into a technology partnership targeting infectious disease • Immunoprecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation • Commenced trading on Nasdaq stock exchange • Announced...
March 16th, 2021
ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies
The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy VICTORIA, BRITISH COLOMBIA March 16, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”)...
March 3rd, 2021
ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference)
Management to provide corporate update on emerging SARS-CoV-2 variants of concern, (UK, S. African and Brazilian) VICTORIA, British Columbia, March 4, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a...
March 2nd, 2021
ImmunoPrecise To Participate in BiotechGate Digital Partnering Event
ImmunoPrecise will be participating in the Biotechgate Digital Partnering event being hosted virtually May 3-7, 2021. The digital partnering event is designed to support business development through pre-arranged 1-on-1 meetings. Learn more about the...
February 3rd, 2021
IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million
VICTORIA, BRITISH COLUMBIA February 3, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, due to demand,...
January 6th, 2021
ImmunoPrecise Antibodies to Participate in January Conferences
VICTORIA, British Columbia, January 6 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennifer Bath, ImmunoPrecise’s Chief Executive Officer,...
December 10th, 2020
ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2
VICTORIA December 11, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATD) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a...
November 25th, 2020
ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500™
VICTORIA, November 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced it ranked 240 on ...
November 19th, 2020
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease
VICTORIA, November 19, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into...
November 9th, 2020
ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement
VICTORIA, BC, November 9, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has filed a...
November 3rd, 2020
ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership
VICTORIA, November 3, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced a research partnership with...
October 27th, 2020
ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products
VICTORIA, October 27, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, Talem...
October 8th, 2020
IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test
Also signs Definitive Commercial Agreement with University of Victoria VICTORIA, October 8, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic...
October 6th, 2020
IPA’s CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television
VICTORIA, October 6, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO...
October 5th, 2020
ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends
VICTORIA, October 05, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO...
September 28th, 2020
IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television
VICTORIA, September 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath,...
September 25th, 2020
ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials
VICTORIA, September 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, and LiteVax BV (Oss, the Netherlands), today announced...
September 17th, 2020
ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks
VICTORIA, September 17, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, announce a research collaboration with...
September 10th, 2020
ImmunoPrecise Commences Application Process to Dual List on NASDAQ
VICTORIA, September 10, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) ( FSE:TQB2), a provider of best-in-class therapeutic antibody discovery capabilities for the global pharmaceutical and biotech...
September 9th, 2020
ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
VICTORIA, September 9, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting...
September 1st, 2020
ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020
Reports rapid advancement of COVID-19 antibody programs;combination studies achieve nearly complete neutralization of SARS-CoV-2 VICTORIA, August 31, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF)...
July 31st, 2020
IPA’s Human Anti-SARS-CoV-2 Therapeutic Antibodies Demonstrate Synergistic Neutralization
VICTORIA, July 31, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is pleased to announce that additional characterization...
July 20th, 2020
IPA Announces Repayment of Remaining 2018 Debentures and $3,811,205 in Warrant Exercises
VICTORIA, July 20, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announces that it has repaid the...
July 13th, 2020
Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA’s Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies
IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals’ genetically engineered OmniRat® strains producing human antibodies VICTORIA, July 13, 2020 / – IMMUNOPRECISE...
June 22nd, 2020
Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2
Oss, Netherlands, June 22, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), and LiteVax BV (“LiteVax”) (the Netherlands), today announced that a preclinical study to analyze the...
June 11th, 2020
Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise’s European Subsidiary, UPE
Utrecht, June 11, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA, OTC QB: IPATF, Germany: TQB2) subsidiary U-Protein Express BV (“UPE”) today announced the availability of its new recombinant SARS-CoV-2...
June 4th, 2020
ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)
VICTORIA, June 4, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is...
April 17th, 2020
ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery
We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical trials. VICTORIA, April 17, 2020/ –...
March 30th, 2020
ImmunoPrecise’s Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus for PolyTope™ mAb Therapy Program
We caution that this is still early stage research and development and is not making any express or implied claims that it has the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical...
March 10th, 2020
ImmunoPrecise Reports Record Quarterly and Nine Month Revenue and Positive Adjusted EBITDA
VICTORIA, March 10, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2020 third quarter ended January 31, 2020. Revenue. The Company posted a...
March 9th, 2020
ImmunoPrecise Announces Debt Settlement of Previously Issued Debentures
VICTORIA, March 6, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that it wishes to settle up to $796,875 of previously issued debentures including interest by issuing up to 1,328,125...
March 2nd, 2020
ImmunoPrecise Announces Artificial Intelligence Collaboration With EVQLV To Accelerate Vaccine And Antibody Discovery For SARS-CoV-2 Coronavirus
The partnership with the New York-based artificial intelligence company will focus on high-throughput computational antibody design to derive novel leads from ImmunoPrecise’s platforms and accelerate Coronavirus therapeutic antibody discovery and...
January 20th, 2020
ImmunoPrecise integrates SGI-DNA’s benchtop automated DNA printer to accelerate antibody discovery and manufacturing services
VICTORIA, SAN DIEGO, and UTRECHT, January 20, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, and...
December 17th, 2019
ImmunoPrecise Announces Record Quarterly Revenue and Significantly Expands Gross Margins
VICTORIA, December 17, 2019/- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) announces today that it has released its financial results for the second quarter ended October 31, 2019. The financial statements...
October 14th, 2019
ImmunoPrecise Exhibiting at European Antibody Congress in Basel, October 15-19, 2019
ImmunoPrecise Antibodies will attend the Festival of Biologics held at the Congress Centre, Basel October 15-19th. The Festival of Biologics is a combination of four incredible conferences, the European Antibody Congress, the World Immunotherapy...
October 3rd, 2019
ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom
VICTORIA, October 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment...
October 1st, 2019
ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer
VICTORIA, October 1st, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment...
September 22nd, 2019
ImmunoPrecise to Lead Roundtable and Present Poster at 2019 West Coast Antibody Therapeutics Xchange
As innovative leaders in the field of antibody discovery, we are pleased to sponsor and lead group discussions at the 2019 West Coast Antibody Therapeutics Xchange. The unique format of hubXchange events formatting allows for a more in-depth...
September 16th, 2019
ImmunoPrecise Exhibiting at Discovery on Target in Boston, MA, on September 16-19
ImmunoPrecise Antibodies will participate in the 17th Annual Discovery on Target (DOT) being held Boston, MA September 16-19. With over 1,300 attendees and a variety of keynote speakers, training seminars, short courses, roundtables, and networking...
August 7th, 2019
Shareholder Lab Visit: ImmunoPrecise Antibodies – Canada
ImmunoPrecise Antibodies Ltd invites our shareholders to visit our Victoria Lab on Wednesday, August, 14th, followed by a social at Canoe Brewpub in Downtown Victoria. Shareholders will have the opportunity to tour our labs and meet with Dr....
June 26th, 2019
ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform
VICTORIA, June 26, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that from this point forward it will...
June 10th, 2019
ImmunoPrecise Attending & Exhibiting at Antibody Engineering & Therapeutics Europe 2019
The ImmunoPrecise Antibodies team will be exhibiting at Antibody Engineering & Therapeutics (AET) Europe 2019 in Amsterdam, NL from June 11th-13th, 2019. AET Europe is the industry’s European meeting for Antibody and Protein Therapeutic Science,...
May 30th, 2019
ImmunoPrecise’s Diversified Offerings Spark Surge in Requests for use of Nine Different Transgenic Animal Strains on Innovative Service Platforms in B cell Select™️ and DeepDisplay™️
VICTORIA, May 30, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces that its proprietary, high-throughput B cell and phage display platforms have garnered a lot of attention as of...
April 16th, 2019
ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, April 16, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today that Jennifer Bath, President and CEO of ImmunoPrecise Antibodies, will present at the upcoming 2019 Bloom...
April 4th, 2019
ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market
Victoria, British Columbia, Canada, April 03, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture...
April 4th, 2019
ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics
VICTORIA, April 4, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem Therapeutics (Talem). Talem is focused...
April 2nd, 2019
ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform – ImmunoPrecise Launches Large-Scale Discovery Program with US Pharma Company
VICTORIA, April 2,2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the expansion of their service offerings in therapeutic antibody discovery to select rare, fully human antibodies using...
March 28th, 2019
ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results – Revenues Up 228% For The First 9 Months of Fiscal 2019
VICTORIA, March 27, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q3 ended January 31, 2019. The financial statements and related management’s...
March 20th, 2019
Meet Us at European Antibody Therapeutics Xchange
ImmunoPrecise to Lead Scientific Round-table Discussion and Poster Session at hubXchange’s European Antibody Therapeutics event. At hubXchange’s European Antibody Therapeutics event, held in Munich on March 21st, Dr. Debby Kruijsen will lead a...
March 15th, 2019
ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV
VICTORIA, March 15, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today announces that Jos Raats, Ph.D., has resigned from the position of Managing Director of ModiQuest Research B.V. in order...
February 27th, 2019
Meet Us at the Americas Antibody Congress 2019
ImmunoPrecise will be exhibiting at the Americas Antibody Congress 2019 at Festival of Biologics, a multi-streamed, co-located conference & technology exhibition March 4 – 5, 2019 at the Grand Hyatt, in San Diego, California. Connect with us at...
February 19th, 2019
ImmunoPrecise Antibodies Collaborates with FIND to Help Advance New TB Diagnostic Test
VICTORIA, February 19, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New...
February 14th, 2019
Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts.
VICTORIA, February 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office in Cambridge, Massachusetts. ImmunoPrecise Antibodies Ltd is a...
January 14th, 2019
ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer
VICTORIA, January 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as Chief Financial Officer. Lisa Helbling brings over 30 years of...
December 25th, 2018
ImmunoPrecise Hires Jason Orloske as Vice President Operations
VICTORIA, Dec. 26, 2018 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for ImmunoPrecise Antibodies...
December 6th, 2018
Meet Us at Antibody Engineering & Therapeutics 2018
ImmunoPrecise will be attending Antibody Engineering & Therapeutics 2018, the annual meeting of The Antibody Society, where you can find the latest science, technologies and partners in antibody engineering, immunobiology, and next generation...
November 26th, 2018
ImmunoPrecise Antibodies Ltd. Discusses Target Customer Base and Growth Drivers in an Interview with StockNewsNow
ImmunoPrecise’s CEO and President, Dr. Jennifer Bath spoke with SNNLive at the SmallCap Discoveries Conference 2018 in Vancouver. Check Out the Video to Find out More On: The overview and history of ImmunoPrecise Antibodies, what makes IPA unique in...
October 29th, 2018
ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform
Victoria, British Columbia, Canada, October 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through our recent growth in Europe. Our advanced...
October 2nd, 2018
ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms
Victoria, British Columbia, Canada, October 2nd, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offerings...
September 24th, 2018
US West Coast Antibody Engineering Xchange 2018
ImmunoPrecise at US West Coast Antibody Engineering Xchange 2018 ImmunoPrecise is excited to announce that we will be attending hubXchange’s US West Coast Antibody Engineering Xchange in San Diego on September 26th, 2018. HubXchange specializes in...
September 21st, 2018
Meet with ImmunoPrecise at the 16th Annual Discovery on Target
ImmunoPrecise is excited to be exhibiting at this year’s Discovery on Target conference from September 25th to 28th in Boston, MA. Visit booth #213 at the Sheraton Boston, and discover how ImmunoPrecise can further your therapeutic antibody...
July 18th, 2018
ImmunoPrecise Accelerates the Launch of its European, Full-service, B-cell Facility
VICTORIA, July 18, 2018 /CNW/ – To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division...
June 19th, 2018
ImmunoPrecise Closes Private Placement Financing
Victoria, British Columbia, Canada, June 19, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by...
June 4th, 2018
Antibody Engineering & Therapeutics Europe June 5th-7th, 2018 – Meet with ImmunoPrecise & ModiQuest Research
ImmunoPrecise & ModiQuest Reseach B.V. will be exhibiting at the upcoming Antibody Engineering & Therapeutics Europe in Amsterdam! Come visit us at Booth #10 Featured Services B cell Selection Technologies Advanced Hybridoma Development Antibody...
January 18th, 2018
ImmunoPrecise Engages San Francisco Based Lightpath Capital as A Key Partner in its Financing Strategy
Victoria, British Columbia, Canada, January 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged LightPath Capital, Inc. (“LightPath”) to act as its financial advisor and...
January 2nd, 2018
ImmunoPrecise Antibodies Attending J.P. Morgan Healthcare Conference Week January 8-11, 2018
ImmunoPrecise will be attending the J.P. Morgan 36th Annual Healthcare Conference running from January 8-11, 2018 in San Francisco, California. Thirty-five years ago, J.P. Morgan launched Wall Street’s premier investor conference focused exclusively...
December 8th, 2017
Meet ImmunoPrecise at Antibody Engineering & Therapeutics 2017
If you will be attending the Antibody Engineering & Therapeutics show, make sure to stop by booth #219! This is a great opportunity to meet with our scientists, discuss your research, and start a conversation on how ImmunoPrecise would go about...
November 20th, 2017
ImmunoPrecise Realigns Senior Management
Victoria, British Columbia, Canada, November 20, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the realignment of its senior management team as Dr. James Kuo, Chair of the Board, assumes the...
October 1st, 2017
ImmunoPrecise Antibodies Reports Q1 2018 Results
ImmunoPrecise Develops Humanizing Platforms to Significantly Grow Core Business. Increases Operational Efficiency and Expands Capacity to Scale Quickly September 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”)...
August 29th, 2017
ImmunoPrecise Announces R&D Success Using The OmniAB® Platform to Develop Fully Human Antibodies
Victoria, British Columbia, Canada, August 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization (“CRO”) for developing human monocolonal...
August 24th, 2017
ImmunoPrecise Antibodies Reports 2017 Annual Results – Revenues Up 39% Over Fiscal 2016
Victoria, British Columbia, Canada, August 24, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) yesterday reported its financial results for the fourth quarter ended April 30, 2017 and provides a...
August 24th, 2017
ImmunoPrecise Completes Acquisition of U-Protein and Private Placement of $5.25 Million
Victoria, British Columbia, Canada, August 23, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has completed the acquisition of U-Protein Express BV (“U-Protein”) whereby the Company has acquired...
August 11th, 2017
ImmunoPrecise Signs Definitive Agreement with U-Protein
Victoria, British Columbia, Canada, August 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, further to its news release dated July 4, 2017, it has signed a definitive agreement with U-Protein...
August 3rd, 2017
ImmunoPrecise Announces Expansion Into Humanizing Technologies and Platforms
Victoria, British Columbia, Canada, August 3, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has completed significant steps that enhance its ability to deliver humanized monoclonal...
August 2nd, 2017
ImmunoPrecise Increases Financing to $5.25 Million
Victoria, British Columbia, Canada, August 2, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to announce that it has further increased...
February 28th, 2017
Immunoprecise Appoints Contact Financial for Investor Relations and Launches New Website For Its Custom Antibody Services
Victoria, British Columbia, Canada, March 1, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: TQURF), a life sciences technology and product company engineering custom antibodies, announced that it has appointed...